Biodexa Debt To Assets from 2010 to 2024

BDRX Stock   4.98  0.41  8.97%   
Biodexa Pharmaceticals Debt To Assets yearly trend continues to be fairly stable with very little volatility. Debt To Assets will likely drop to 0.01 in 2024. During the period from 2010 to 2024, Biodexa Pharmaceticals Debt To Assets regression line of annual values had r-squared of  0.63 and arithmetic mean of  0.27. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.0125
Current Value
0.0119
Quarterly Volatility
0.39662882
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.9 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.34. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Biodexa Debt To Assets Regression Statistics

Arithmetic Mean0.27
Geometric Mean0.07
Coefficient Of Variation146.44
Mean Deviation0.33
Median0.04
Standard Deviation0.40
Sample Variance0.16
Range0.9639
R-Value(0.79)
Mean Square Error0.06
R-Squared0.63
Significance0.0004
Slope(0.07)
Total Sum of Squares2.20

Biodexa Debt To Assets History

2024 0.0119
2023 0.0125
2020 0.0109
2019 0.16
2018 0.049
2017 0.13
2016 0.0366

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Debt To Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.